Recent Comments

Comment RSS

Avastin News and Research RSS Feed - Avastin News and Research

Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

Comprehensive report on world cancer therapies market

20. November 2009 01:37
Research and Markets (http://www.researchandmarkets.com/research/4b82d8/cancer_therapies) has announced the addition of the "Cancer Therapies - Global Market Opportunities" report to their offering. [More]

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

18. November 2009 04:43
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. [More]

Press conference highlights emerging treatments in pancreatic cancer

18. November 2009 03:30
As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. [More]

Genentech submits sBLAs to the FDA for Avastin

17. November 2009 03:36
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy. [More]

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

17. November 2009 01:58
Targeting the normal cells that surround cancer cells within and around a tumor is a strategy that could greatly increase the effectiveness of traditional anti-cancer treatments, say researchers at The Wistar Institute. [More]

Comprehensive report on CRC market

12. November 2009 01:41
Research and Markets (http://www.researchandmarkets.com/research/476754/pipeline_insight) has announced the addition of the "Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine" report to their offering. [More]

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

9. November 2009 08:41
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , ,

Idera Pharmaceuticals announces financial results for the third quarter of 2009

5. November 2009 07:54
Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. [More]

Gastric cancer drug market to double to nearly $1.5 billion in 2018

4. November 2009 08:51
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , ,

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

3. November 2009 03:54
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. [More]

Third-quarter 2009 financial results of Antigenics announced

29. October 2009 07:45
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted. [More]

Report on the future market potential for monoclonal antibodies

27. October 2009 08:28
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment [More]

Report on immunotherapies and vaccines for nontraditional indications

27. October 2009 07:23
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications [More]

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

26. October 2009 07:48
Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA. [More]

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

9. October 2009 11:33
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.